KYTHERA Biopharmaceuticals Added to Russell 3000, 2000, Global and Microcap Indexes

KYTHERA Biopharmaceuticals Inc. today announced that the company has been added to each of the broad-market Russell 3000® Index, the Russell 2000® Index, the Russell Microcap® Index and the Russell Global® Index as part of Russell's quarterly IPO additions effective as of the close of trading on December 21, 2012.

“We're extremely pleased to be included in these widely known Russell indexes”

"We're extremely pleased to be included in these widely known Russell indexes,” said Keith Leonard, KYTHERA’s President and CEO. Buy Furacin (Nitrofurazone) pills online without prescription “We are committed to building long-term value for our stockholders and we value the significance and increased visibility within the investment community that can result from inclusion in these indexes.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in institutional assets currently are benchmarked to them.
The annual reconstitution of Russell’s U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 Index also serves as the U.S. component of the Russell Global® Index.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is a potential first-in-class, injectable treatment currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable “double chin.” KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding KYTHERA, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the increased visibility within the investment community that can result from inclusion in the indexes. Such forward-looking statements involve substantial risks and uncertainties that may differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks included under the heading “Risks Related to Our Common Stock” included in the Risk Factor sections of KYTHERA’s reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. KYTHERA undertakes no obligation to update or revise any forward-looking statements.

A Focus on Specialty Pharmacy at Las Vegas Pharmaceutical Conference

Specialty pharmacy takes center stage when leading experts in the pharmaceutical and biotech manufacturers' industries gather in Las Vegas, September 19-21 to discuss the current changes and trends developing in our healthcare system that directly influence the specialty arena. Specialty pharmacy, which develops and markets high-priced medications and treatments used to manage diseases, is gaining more attention as providers and insurers look to streamline delivery and reimbursement policies around these prescribed therapies. Buy Actos (Pioglitazone Hydrochloride) pills online without prescription

“Management of New Drugs on the Medical Benefit”

“The specialty drug trend and healthcare reform are pushing the industry to evolve,” said Kevin Cast, Vice President of Strategy and Contracting for United BioSource Corporation. “Now more than ever manufacturers need a fresh approach to commercialization, access, adherence, reimbursement and safety.”
This newly expanded focus-area at the September Managed Markets Summit will feature more than a dozen distinguished faculty members from major corporations discussing the challenges and trends of selling specialty products in an evolving healthcare marketplace.
Summit presenters include:

• Kirby Eng, RPh, Director, Medical Benefit Drug Management, CVS Caremark Corporation
  "Managing the Oncolytic Space"

• Christine Strahl, Pharm.D., MBA, BCPS, Specialty Pharmacy Program Manager, HealthPartners, Inc.
  "Management of New Drugs on the Medical Benefit"
• Mark Montgomery, Chief Executive Officer & President, Axium Healthcare Pharmacy, Inc.
  "Biotech and Specialty Pharmacy Contracting"

• Julie Thomas, Director, Pharma/Biotech Sales, Exactus Pharmacy Solutions (WellCare)
  "Competing With Products Across Medical and Pharmacy Benefits: What You Should Know"

Additional conference topics include:

• The shifting paradigms in specialty drug management
• How new technologies may affect payers and specialty pharmacy providers
• Payer strategies for managing specialty medications
• What healthcare reform means in today’s specialty environment

The Pinsonault Managed Markets Summit takes place at The Cosmopolitan of Las Vegas, September 19-21, 2012. The cost is $2,595 per person with discounts available to groups of five or more.
About Pinsonault
Pinsonault, a division of Decision Resources Group, is dedicated to and focused on delivering high quality, Managed Markets specific, business and training solutions within the pharmaceutical and biotech industries. The organization strives to create customer specific solutions that provide valuable strategic insight and results oriented tactical tools enabling clients to identify and capitalize on Managed Markets business opportunities.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.

No BPA Ban On Cans And Food Packaging, Says FDA

Bisphenol A, also known as BPA will not be banned from cans and other food/drinks packagings, the Food and Drug Administration (FDA) announced yesterday, saying that those who requested the ban had not provided enough compelling data. The most appropriate course of action, the Agency added, is for current studies to proceed, including some federally funded ones, and to review their findings at a later date.

BPA, chemical formula (CH₃) ₂C(C₆H₄OH)₂, is an organic compound. It is poorly soluble in water, but soluble in organic solvents. BPA was found to have slight hormone-like properties when ingested (animal studies). There is concern that BPA used in food packaging and cans of foods and drinks may be harmful to human health. Buy Droxia pills online without prescription

A 2010 FDA report expressed concern about BPA exposure to young children, infants and fetuses. Canada declared BPA a toxic substance in 2010, the first nation to do so. The EU (European Union) and Canada have prohibited BPA use in baby bottles.

Bisphenol A has been used for fifty years to extend the shelf life of canned foods and drinks. It is used in the resin lining of food and drinks cans.

Even though US authorities have not banned BPA from baby bottles and cups, manufacturers have stopped using BPA-containing polycarbonates in such products, after intense pressure from consumer groups. Food and drinks companies have taken different attitudes towards the chemical. While the Coca-Cola Company says BPA is safe and will continue using the chemical in its beverage cans, Campbell Soup Company says it is phasing it out.

In 2008, the Natural Resources Defense Council (NRDC) sent a petition to the FDA, requesting the banning of BPA in food and drinks packaging.

Animal studies on BPA

Animal studies have shown that BPA mimics estrogen, a female hormone. Exposure early in life to BPA is linked to:

• Pre-cancerous changes in the prostate gland
• Pre-cancerous changes in the mammary glands
• Brain development is altered, leading to early puberty onset, as well as some behavioral changes
• Lower sperm counts
• Enlarged prostate gland
• Chromosomal abnormalities in eggs
• Obesity and insulin resistance

Nobody knows whether what has been found to occur in animals might also apply to humans.